Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

167results about How to "No immune rejection" patented technology

Acellular biological patch, preparation method and apparatus thereof

ActiveCN103251987ATissue structure is softEnsure safetySurgeryCoatingsChemistryOn cells
The invention relates to an acellular biological patch, a preparation method and an apparatus thereof. In the invention, small intestines of pigs are taken as raw materials, which are subjected to a series of decellularization treatment by means of an acid, hydrogen peroxide, a mixed solution of high salt and alkali so as to obtain the acellular biological patch. According to the preparation method, after treatment by the hydrogen peroxide, the mixed solution of high salt and alkali can be employed to conduct twice recycling treatment, thus reaching the effects of thorough decellularization and antigen removal. The employment of a transverse and longitudinal alternating laying way maintains uniformity of the patch's mechanical properties, the tensile strength, suture tear force, tear strength and other mechanical indexes can well meet clinical demands, thus facilitating surgical suture operation. The employed drying mode has no need of any adhesive and suture line for fixation, so that a natural three-dimensional support structure of the product is maintained, and after implantation into the human body, no strong inflammatory response and immunological rejection response can occur. The patch has no toxicity on cells, so that infection and adhesion cannot occur in a repair process. The acellular biological patch provided in the invention is suitable for repair of body tissue defects and soft tissue injuries, and also can be used in the bioengineering field to serve as the tissue for reinforcing repair of membranous defects and infected wounds and serve as a biological scaffold material, etc.
Owner:SHAANXI BIO REGENERATIVE MEDICINE CO LTD

Method and application for inducing human umbilical cord mesenchyme stem cells to be differentiated into testicular interstitial cells

The invention discloses a method and application for inducing human umbilical cord mesenchyme stem cells to be differentiated into testicular interstitial cells. The method comprises the following step of culturing human umbilical cord mesenchyme stem cells of patients suffering from adenovirus and carrying mice steroidogenic factor-1 genes in a DMEM-F12 culture solution containing 0.3-3ng / ml of luteinizing hormone, 200-800mu M of dibutyryl cyclic adenosine monophosphate, 5*10<-6>-5*10<-4>M of all-trans retinoic acid (ATRA), 10mU / ml of human chorionic gonadotropin and 2.4uM of adrenocorticotrophic hormone for a week. Induced by the method in the invention, the human umbilical cord mesenchyme stem cells can be differentiated into testicular interstitial cells in vitro and provides important sources of cells for treating testosterone shortage by the cell replacing method or the genetic method.
Owner:JINAN UNIVERSITY

Functional tissue engineering material for nerve repair, preparation method and use thereof

The present invention provides a functional tissue engineering material for nerve repair. The functional tissue engineering material comprises human amnion, a neurotrophic factor specifically bound with the collagen, and an inhibitor fixedly bound with calpain. The present invention further provides a preparation method for the functional tissue engineering material, wherein neurotrophic factor fusion protein specifically bound with the collagen binding domain and an inhibitor for cross-linking calpain are constructed to form the functional tissue engineering material for guiding nerve repair, such that the human amnion can be specifically bound with the neurotrophic factor so as to effectively promote nerve repair, the regeneration nerve forms correct synaptic connections, the nerve re-injury effect of calpain can be eliminated, and the material can be used for targeting treatment of central nerve injury diseases and neural function repair.
Owner:PLA NAVY GENERAL HOSIPTAL

Stem cell repairing material as well as preparation method and application thereof

The invention relates to a stem cell repairing material as well as a preparation method and application thereof. The stem cell repairing material comprises a stem cell and a cell carrier, wherein the stem cell is an autologous adipose-derived mesenchymal stem cell (ADSC) with a concentration of 105-108/ml, and the cell carrier is autoserum, normal saline (0.9%) or a glucose injection (5%). In the invention, adopted seed cells are prepared through separating and purifying autologous adipose tissues of patients, thereby avoiding the ethical disputes and the immunological rejection. The material drawing of the adipose tissues can be performed by using an instrument suction method, which is simple in operation and can bring less traumas and pains to the patients. The cell carrier used in the invention is the autoserum, normal saline (0.9%) or glucose injection (5%), therefore, the cell carrier mixed with mesenchymal stem cells and other ingredients can be injected into the patents by virtue of syringes. By using the stem cell repairing material provided by the invention, the operation process is simple, no scar is left, and the wounds and pains for the patients are avoided, therefore, the stem cell repairing material can be easily accepted by the patients.
Owner:王影

Recombinant humanized III-type collagen and preparation method thereof

The invention provides a recombinant humanized III-type collagen. The recombinant humanized III-type collagen has a triple helix structure, and has an amino acid sequence reducing a humanized III-typecollagen alpha-1 chain and including 1068 amino acids. The invention further provides a preparation method of the recombinant humanized III-type collagen, wherein the prolyl hydroxylase of PBCV-1 includes 209 amino acids, and the base sequence is optimized according to the codons of saccharomyces cerevisiae. Compared with the prior art, the preparation method has the advantages that the triple helix is formed in vitro from collagen chains by utilizing the prolyl hydroxylase; and the saccharomyces cerevisiae expression system adopted by the invention is applicable to large-scale amplificationwithout endotoxin or later removal, the preparation cost is low, and the protein expression quantity is further improved. The recombinant humanized III-type collagen is excellent in stability, the amino acid composition of the recombinant humanized III-type collagen is almost completely the same as that of the alpha-1 chain of a natural collagen, and no immunological rejection can be generated when the recombinant humanized III-type collagen is applied to a human body. The recombinant humanized III-type collagen is good in biocompatibility and can be widely applied to surgical treatment and cosmetic medical industry.
Owner:叶华

Culture method of transgenic swine, and applications thereof

The invention discloses a culture method of transgenic swine. The culture method at least comprises following steps: swine primary somatic cells are introduced into messenger RNA coded cell reprogramming genes and / or miR302 / 367 clusters for inductive production of RNA inductive multipotential stem cells; under the effect of Cas9-gRNA and CRE homologous recombinase, swine toxic genes are knock out,and knock of a plurality of human gene segments is carried out, human derived vWF gene is used for replacing swine endogenous vWF gene, and obtaining PERV-virus-inactivated human-immunological-rejection-free coagulation-incompatibility-free genes; clean target cell lines without off-target-effect are selected, and are culture into swine somatic cells; somatic cell nucleus transfer technology is adopted to treat swine somatic cells so as to obtain transgenic swine. The transgenic swine possesses following advantages, permanent PERV virus expression is inhibited permanently, human immunologicalrejection is avoided, and blood coagulation compatibility is achieved, and can be taken as human heterogeneous organ, tissue, and cell donors.
Owner:GENEO MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products